Completed

Evaluation of the TorEx Lung Perfusion System in Clinical Lung Transplantation: A Safety Study

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

TorEx Lung Perfusion System

Device
Who is being recruted

From 18 to 80 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: December 2022
See protocol details

Summary

Principal SponsorUniversity Health Network, Toronto
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: December 6, 2022

Actual date on which the first participant was enrolled.

Lung transplantation is a life-saving and life-prolonging therapy for patients with end-stage lung disease. However, the number of patients listed for lung transplantation exceeds the number of available donor lungs, leading to long wait times, deterioration in health and death of some listed patients. One way to address this issue is to reduce the number of donor lungs that are deemed unusable (declined) for transplantation. Often, donor lungs are declined for transplantation based on questionable function or inability to fully assess the organ in the donor. Due to this reason, up to 80% of potentially suitable lungs may be discarded. As a result, ex vivo lung perfusion (EVLP) was developed. EVLP is a technique that enables the donor lungs to function in near physiological conditions outside the body, allowing surgeons to evaluate the suitability of the donor lungs for transplantation. Using this technique, centers have reported the recovery of around 70% of donor lungs that would have otherwise been deemed unusable and discarded. The first generation Toronto EVLP technique started as a clinical trial in 2008 and became a part of the clinical standard of care at Toronto General Hospital in 2011. Since then, many clinical studies have shown that short- and long-term outcomes of recipients who received donor lungs assessed by the Toronto EVLP system were similar to those who received donor lungs deemed suitable to go straight to transplantation. In partnership with Traferox Technologies Inc., surgeons and research team members developed the second generation TorEx Lung Perfusion System, which addresses engineering design limitations of the original Toronto EVLP system. It optimizes the Toronto EVLP technique by combining all the necessary equipment required to perform the procedure, while placing their controls within a central location. The technique of perfusion and ventilation as well as the perfusate solution remain the same between the two EVLP systems. Prior to this study, the TorEx Lung Perfusion System has not been used in clinical human lung transplantation. The first purpose of this study is to look at the safety of using the TorEx Lung Perfusion System in 20 consented recipients. The second purpose to compare post-transplant outcomes between recipients who received donor lungs assessed by the TorEx Lung Perfusion System and a historical cohort of recipients who received donor lungs that were assessed by the first generation Toronto EVLP system.

Official TitleEvaluation of the TorEx Lung Perfusion System in Clinical Lung Transplantation: A Safety Study
Principal SponsorUniversity Health Network, Toronto
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

20 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

Recipient Inclusion Criteria * Actively listed for primary lung transplantation * Written, informed consent provided * 18-80 years old Recipient Exclusion Criteria * Re-transplantation * Multi-organ transplantation * Participation in another interventional trial Donor Inclusion Criteria * Age ≤70 years old * Ex vivo lung perfusion clinically indicated for donor lungs Donor Exclusion Criteria * Age \>70 years old * Donor lungs suitable to go straight to transplantation EVLP Transplant Suitability * Pulmonary vein PO2 \> 400mmHg * Stability or improvement of other lung function parameters during EVLP (PVR, Compliance, Airway Pressures) * Surgeon clinically satisfied with lung evaluation

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Toronto General Hospital, University Health Network

Toronto, CanadaOpen Toronto General Hospital, University Health Network in Google Maps
CompletedOne Study Center